DekaBank Deutsche Girozentrale’s Xenon Pharmaceuticals XENE Stock Holding History

DekaBank Deutsche Girozentrale’s Portfolio XENE Stock Details XENE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.16M	Hold	39,000	–	–	﹤0.01%	684
2026 Q1	$2.2M	Hold	39,000	–	–	﹤0.01%	683
2025 Q4	$1.82M	Hold	39,000	–	–	﹤0.01%	784
2025 Q3	$1.51M	Hold	39,000	–	–	﹤0.01%	802
2025 Q2	$1.26M	Hold	39,000	–	–	﹤0.01%	816
2025 Q1	$1.31M	Hold	39,000	–	–	﹤0.01%	803
2024 Q4	$1.5M	Hold	39,000	–	–	﹤0.01%	803
2024 Q3	$1.5M	Hold	39,000	–	–	﹤0.01%	815
2024 Q2	$1.46M	Hold	39,000	–	–	﹤0.01%	814
2024 Q1	$1.67M	Hold	39,000	–	–	﹤0.01%	795
2023 Q4	$1.8M	Buy	39,000 +19,000	+95%	+$671K	﹤0.01%	791
2023 Q3	$707K	Hold	20,000	–	–	﹤0.01%	940
2023 Q2	$772K	Hold	20,000	–	–	﹤0.01%	929
2023 Q1	$708K	Hold	20,000	–	–	﹤0.01%	948
2022 Q4	$781K	Hold	20,000	–	–	﹤0.01%	944
2022 Q3	$721K	Buy	20,000 +7,600	+61%	+$273K	﹤0.01%	963
2022 Q2	$378K	Hold	12,400	–	–	﹤0.01%	1072
2022 Q1	$373K	Buy	12,400 +1,100	+10%	+$32.9K	﹤0.01%	1113
2021 Q4	$359K	Buy	11,300 +300	+3%	+$8.96K	﹤0.01%	1168
2021 Q3	$162K	Hold	11,000	–	–	﹤0.01%	1242
2021 Q2	$196K	Hold	11,000	–	–	﹤0.01%	1224
2021 Q1	$190K	Hold	11,000	–	–	﹤0.01%	1190
2020 Q4	$157K	Buy	+11,000	New	+$129K	﹤0.01%	1213

Other funds holding XENE

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Jupiter Topco New York $245B AUM

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

DekaBank Deutsche Girozentrale's XENE Position: Q2 2026 in Review

DekaBank Deutsche Girozentrale held its Xenon Pharmaceuticals (XENE) position steady in Q2 2026 at 39,000 shares worth $2.16M. The position accounts for ﹤0.01% of the portfolio, ranked #684.

DekaBank Deutsche Girozentrale first reported a position in XENE in Q4 2020 and has held it in 23 quarters since. The position peaked at $2.2M in Q1 2026. 315 funds tracked by Wall St. Rank hold XENE as of Q2 2026.

DekaBank Deutsche Girozentrale held 39,000 shares of Xenon Pharmaceuticals worth $2.16M as of Q2 2026.
DekaBank Deutsche Girozentrale left its Xenon Pharmaceuticals share count unchanged in Q2 2026.
Xenon Pharmaceuticals made up ﹤0.01% of DekaBank Deutsche Girozentrale's portfolio in Q2 2026, its #684 holding.
DekaBank Deutsche Girozentrale first reported a position in Xenon Pharmaceuticals in Q4 2020 and has held it in 23 quarters since.
DekaBank Deutsche Girozentrale's Xenon Pharmaceuticals position peaked at $2.2M in Q1 2026.
315 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q2 2026.

Based on DekaBank Deutsche Girozentrale's 13F filing for Q2 2026, filed 5 Aug 2026.